|Original language||English (US)|
|Number of pages||6|
|Journal||JAMA Internal Medicine|
|State||Published - May 2022|
ASJC Scopus subject areas
- Internal Medicine
Access to Document
Other files and links
In: JAMA Internal Medicine, Vol. 182, No. 5, 05.2022, p. 559-564.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Evaluation of Evidence-Based Dual Antiplatelet Therapy for Secondary Prevention in US Patients with Acute Ischemic Stroke
AU - Xian, Ying
AU - Xu, Haolin
AU - Smith, Eric E.
AU - Fonarow, Gregg C.
AU - Bhatt, Deepak L.
AU - Schwamm, Lee H.
AU - Peterson, Eric D.
N1 - Funding Information: ConflictofInterestDisclosures:DrXianreportedreceivinggrantsfromtheNational InstituteOnAgingandtheAmericanHeartAssociationduringtheconductofthestudy; grants from Daiichi Sankyo, Janssen Pharmaceuticals, and Genentech outside the submitted work; and personal fees from Boehringer Ingelheim and Portola Pharmaceuticalsoutsidethesubmittedwork.DrFonarowreportedreceivingpersonal fees from Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards Lifesciences, JanssenPharmaceuticals,Medtronic,Merck,andNovartisoutsidethesubmittedwork; servingasAssociateEditorofJAMACardiology;andbeingemployedbytheUniversity of California, which has a patent on an endovascular device. Dr Bhatt reported receiving nonfinancial support from the American Heart Association during the conductofthestudy;nonfinancialsupportfromtheAmericanCollegeofCardiology, SocietyofCardiovascularPatientCare,andAmericanHeartAssociation;grantsfrom Amarin Corporation, AstraZeneca, Bristol Myers Squibb, Eisai, Ethicon, Medtronic, SanofiAventis,TheMedicinesCompany,PLxPharma,AmericanCollegeofCardiology, Roche,Pfizer,ForestLaboratories/AstraZeneca,Ischemix,Cardax,BostonScientific, Amgen, Lilly, Chiesi Farmaceutici, Ironwood Pharmaceuticals, Abbott, Regeneron Pharmaceuticals, PhaseBio, Idorsia, Synaptic, Boehringer Ingelheim, Novo Nordisk, Fractyl Health, Cereno Scientific, Afimmune, Ferring Pharmaceuticals, Lexicon Pharmaceuticals, Contego Medical, CellProthera, MyoKardia/Bristol Myers Squibb, Owkin, HLS Therapeutics, Janssen Pharmaceuticals, 89bio, Garmin, Novartis, NirvaMed, Stasys, Faraday Pharmaceuticals, Javelin Biotech, Reid Hoffman Foundation, Moderna, Beren Therapeutics, Aker BioMarine, and Recardio; personal fees from Duke Clinical Research Institute, Mayo Clinic, Population Health Research Institute, American College of Cardiology, Belvoir Media Group, Slack Publications, WebMD, Elsevier, Society of Cardiovascular Patient Care (now ACC Accreditation Services), HMP Global, Harvard Clinical Research Institute (now Baim Institute for Clinical Research), Journal of the American College of Cardiology, Cleveland Clinic, Icahn School of Medicine at Mount Sinai, Tobesoft, Boehringer Ingelheim, Bayer, Medtelligence/ReachMD, CSL Behring, MJH Life Sciences, Level Ex, K2P, Canadian MedicalandSurgicalKnowledgeTranslationResearchGroup,ArnoldandPorter,Piper Sandler,andCowen;andothersupportfromFlowCo,PLxPharma,Takeda,Medscape Cardiology, Regado Biosciences, Boston VA Research Institute, Clinical Cardiology, VeteransAffairs,St.JudeMedical(nowAbbott),Biotronik,Cardax,BostonScientific, Merck, Svelte, PhaseBio, Boehringer Ingelheim, Novo Nordisk, Cereno Scientific, CardiovascularSystemsInc.,CellProthera,MyoKardia/BristolMyersSquibb,Janssen Pharmaceuticals, Novartis, NirvaMed, and Philips, all outside the submitted work. Dr Schwamm reported receiving personal fees from Genentech, Penumbra, and Diffusion Pharmaceuticals and grants from Medtronic, National Institute of Neurological Disorders and Stroke, and National Institutes of Health’s StrokeNet outsidethesubmittedwork.DrPetersonreportedreceivinggrantsfromGenentech, JanssenPharmaceuticals,BristolMyersSquibb,andAmgenduringtheconductofthe study. No other disclosures were reported. Funding Information: Funding/Support: Research reported in this article was supported by the National Institutes of Health National Institute on Aging (R01AG062770 and R01AG066672; Dr Xian). The Get With The Guidelines–Stroke program is provided by the American Heart Association and the American Stroke Association and is sponsored, in part, by Novartis, the Boehringer Ingelheim and Eli Lilly Diabetes Alliance, Novo Nordisk, Sanofi Aventis, AstraZeneca, Bayer, Tylenol, and Alexion Pharmaceuticals. Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. AdditionalContributions:RolandMatsouaka,PhD(DukeClinicalResearchInstitute, Duke University); Daniel T. Laskowitz, MD, MHS (Department of Neurology, DukeUniversitySchoolofMedicine);LesleyMaisch,BA(patientcoinvestigator);Deidre Hannah, MSN, RN (patient coinvestigator); Brian Mac Grory, MBBCh, BAO, MRCP (DepartmentofNeurology,DukeUniversitySchoolofMedicine);WuweiFeng,MD,MS (DepartmentofNeurology,DukeUniversitySchoolofMedicine);MarkJohnson,MD (DepartmentofNeurology,UniversityofTexasSouthwesternMedicalCenter);andEmil Loldrup Fosbøl, MD, PhD (Department of Cardiology, University Hospital of Copenhagen, Rigshospitalet) contributed to the study concept and design and critical revision of the manuscript. These individuals received no compensation beyond their usual salaries for their contributions.
PY - 2022/5
Y1 - 2022/5
UR - http://www.scopus.com/inward/record.url?scp=85127620699&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127620699&partnerID=8YFLogxK
U2 - 10.1001/jamainternmed.2022.0323
DO - 10.1001/jamainternmed.2022.0323
M3 - Letter
C2 - 35344009
AN - SCOPUS:85127620699
SN - 2168-6106
VL - 182
SP - 559
EP - 564
JO - Archives of internal medicine (Chicago, Ill. : 1908)
JF - Archives of internal medicine (Chicago, Ill. : 1908)
IS - 5